Completed NA INTERVENTIONAL 2-arm NCT02113631

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir and Re-assessment of Treatment Duration in Patients With Chronic Hepatitis C

Sponsor: Louis Stokes VA Medical Center

Conditions Cirrhosis Hepatitis C, Chronic

Interventions Boceprevir Peg-IFN Ribavirin Telaprevir

Updated 6 times since 2017 Last updated: Mar 13, 2017 Started: Sep 30, 2011 Primary completion: Apr 30, 2013 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02113631, this NA trial focuses on Cirrhosis and Hepatitis C, Chronic and remains completed. Sponsored by Louis Stokes VA Medical Center, it has been updated 6 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Apr 2017 — Jun 2018 [monthly]

Completed NA

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Apr 2017 [monthly]

Unknown Status NA

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Louis Stokes VA Medical Center

Data source: Louis Stokes VA Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States